Alzheimer’s disease is a degenerative brain condition that impacts millions globally, and it has a lengthy preclinical phase. In fact, it can start many years—even decades—before noticeable symptoms arise.
However, recent research indicates that combining blood biomarkers with self-reported memory issues might shed light on how Alzheimer’s evolves throughout a person’s life.
This suggests that midlife could be a crucial time for enhancing brain health.
In our study, we analyzed data from the renowned Dunedin Study at the University of Otago, which has tracked a group of individuals for over 50 years.
Our findings highlighted a specific protein, pTau181, which seemed linked to self-reported memory and cognitive concerns.
Interestingly, participants were only 45 when assessed—far younger than the typical dementia diagnosis age, usually in the 70s.
In recent years, we’ve seen progress in Alzheimer’s drug treatments. Yet, these aren’t true cures. They primarily slow the disease’s advancement and do not restore lost cognitive abilities.
This reinforces the importance of identifying early signs of Alzheimer’s since treatments may be more effective when started early.
Preventing dementia
Various forms of dementia can exhibit similar symptoms in their early stages, but treatments and progression can differ significantly for each type.
Historically, Alzheimer’s could only be definitively diagnosed after death or through invasive procedures like lumbar punctures.
Now, researchers are working on identifying blood biomarkers that could provide a less invasive means of pinpointing individuals at greater risk for Alzheimer’s disease.
Recognizing the disease early could pave the way for preventive measures, yielding the most significant benefits for brain health and aging.
This could involve lifestyle adjustments, like encouraging physical activity, maintaining social engagements, and addressing modifiable risks such as high blood pressure or hearing impairment.
Preventive strategies tend to be more effective when implemented earlier, which is why studying middle-aged populations is vital to recognize the early risk indicators of Alzheimer’s well before diagnosis.
When forgetfulness becomes a sign of disease
As people age, they often become aware that their memory isn’t quite what it used to be.
While forgetfulness is common and generally benign as one grows older, for some individuals, these memory lapses may signal something more serious.
Recent studies reveal that subtle changes in cognition can occur long before an official diagnosis, possibly being the first sign of the disease’s onset.
Combining biological markers with personal accounts of memory performance could help differentiate between the initial signs of Alzheimer’s and normal aging.
Levels of proteins like pTau181 are notably higher in those with Alzheimer’s, but it’s still unclear when this protein begins to build up.
Our research contributes to the growing evidence that early signs of dementia may appear much earlier than previously thought and that self-reported concerns about cognitive issues can act as initial hints of Alzheimer’s, even in midlife.
Interestingly, we didn’t find a direct correlation between the pTau181 biomarker and MRI brain scans or cognitive tests at age 45.
There might be two explanations for this.
Maybe pTau181 increases in the very early stages of Alzheimer’s when individuals notice subtle memory declines, yet no changes are visible in MRI results.
Alternatively, elevated pTau181 might not indicate Alzheimer’s risk in midlife and could only be relevant for detecting the disease in older individuals.
We still have much to learn and will continue to follow this group as they age to expand on this research.
